The following is an excerpt from an article published by Crain’s Grand Rapid Business on April 1, 2025:
Earning acceptance into a prestigious East Coast business accelerator could be a “game-changer” for a Grand Rapids-based biotech startup developing new treatments forneurodegenerative diseases.
By participating in the spring MassBioDrive cohort for early stage biotechs that aredeveloping breakthrough medical advances, Interactome Biotherapeutics will connect withexperts in the biotech and pharmacy field who can open new opportunities for the company.
Joining the business accelerator “allows us to leverage the extensive expertise and resources of MassBio and its network, accelerating our path to market for our transformative biotherapeutic solutions,” said Adam Koster, CEO and co-founder of Interactome Biotherapeutics.
Interactome is one of five early-stage biotech companies accepted to participate this spring in MassBioDrive, which the approximately 1,800-member trade association launched in 2022.
In that time, more than 30 companies have graduated from the business accelerator, which has sought to steadily reach beyond early-stage startups based in Massachusetts and the East Coast and build partnerships around the U.S. to become a national organization.
“We recognize that there here are brilliant scientists and brilliant science that needs to get to patients that’s not here, and just because it’s not here doesn’t mean it can’t benefit from what we have in Massachusetts,” said Jason Cordeiro, MassBio’s chief operating and innovation officer. “If we can find great science, a great company with a great asset in Michigan that we can help support through our resources and help them develop a drug that’ll help eventually get to a patient that has a severe neurodegenerative disease, that’s an incredibly huge win for our industry, for patients, and for the company in Michigan.”
Read the full story online at Crain’s Grand Rapids Business.